Hostname: page-component-78c5997874-94fs2 Total loading time: 0 Render date: 2024-11-18T08:45:10.224Z Has data issue: false hasContentIssue false
  • English
  • Français

Receptors in the Basal Ganglia

Published online by Cambridge University Press:  05 January 2016

Mark Guttman
Mark Guttman*
Affiliation:
Department of Medicine, Division of Neurology, University of British Columbia, Vancouver
*
Department of Medicine, Division of Neurology, 2211 Wesbrook Mall, Vancouver, B.C., Canada V6T 1W5
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

The study of neurotransmitter receptors aids in the understanding of the normal anatomy, pharmacology, therapeutics and pathophysiology of disease processes involving the basal ganglia. Receptors may be studied in vitro by homogenate binding experiments, enzyme analysis or quantitative autoradiography and in vivo with positron emission tomography. In the substantia nigra (SN), receptors have been identified for somatostatin, neurotensin, substance P, glycine, benzodiazepine and GABA, opiates, dopamine, angiotensin converting enzyme (ACE) and serotonin. The striatum has receptors for dopamine, GABA and benzodiazepines, acetylcholine, opiates, substance P, glutamate and cholecystokinin. GABA and benzodiazepine receptors are also located in the globus pallidus. In Parkinson's disease, striatal dopamine D-2 receptors are elevated in patients that have not received L-DOPA therapy. This supersensitivity is reversed with agonist therapy. Muscarinic binding to cholinergic receptors seems to correlate with dopamine receptors. Delta opiate receptors are increased in the caudate and mu binding is reduced in the striatum. In the SN of patients with Parkinson's disease, there is reduced binding of somatostatin, neurotensin, mu and kappa opiates, benzodiazepine and GABA and glycine. In Huntington's disease, there is reduced binding of GABA and benzodiazepines, dopamine, acetylcholine, glutamate and CCK. There is increased binding of GABA in both the SN and globus pallidus. Glycine binding is increased in the substantia nigra and ACE is reduced.

Type
Research Article
Information
Canadian Journal of Neurological Sciences , Volume 14 , Issue S3 , August 1987 , pp. 395 - 401
Copyright
Copyright © Canadian Neurological Sciences Federation 1987

References

REFERENCES

1.Young, AB, Frey, KA, Agranoff, BW.Receptor Assays: In vitro and in vivo. In: Phelps, M, Mazziotta, J, Shelbert, H, eds. Positron Emission Tomography. Priniciples and Applications for the Brain and Heart. New York: Raven Press, 1986: 73–111.Google Scholar
2.Seeman, P, Ulpian, C, Wreggett, KA, et al. Dopamine receptor parameters detected by [3H] spiperone depend on tissue concentration: analysis and examples. J Neurochem 1984; 43: 221–235.CrossRefGoogle ScholarPubMed
3.Lear, JL.Principles of single and multiple radionuclide autoradio- graphy. In: Phelps, M, Mazziotta, J, Shelbert, H, eds. Positron emission tomography and autoradiography: principles and applications for the brain and heart, New York: Raven Press, 1986: 197–235.Google Scholar
4.Bennett, JP, Wooten, GF. Dopamine denervation does not alter in vivo 3H-spiperone binding in rat striatum: implications for external imaging of dopamine receptors in Parkinson’s disease. Ann Neurol 1986; 19: 378–383.CrossRefGoogle ScholarPubMed
5.Wagner, HN Jr. Images of the brain: past as prologue. J Nucl Med 1986; 27: 1929–1937.Google ScholarPubMed
6.Perlmutter, JS, Raichle, ME.In vitro or in vivo receptor binding: where does the truth lie? Ann Neurol 1986; 19: 384–5.CrossRefGoogle ScholarPubMed
7.Farde, L, Hall, H, Ehrin, E, et al. Quantitative analysis of D2 dopa- mine receptor binding in the living human brain by PET. Science 1986; 231: 258–61.CrossRefGoogle Scholar
8.Huang, SC, Barrio, JR, Phelps, ME.Neuroreceptor assay with positron emission tomography: equilibrium versus dynamic approaches. J Cereb Blood Flow Metab 1986; 6: 515–521.CrossRefGoogle ScholarPubMed
9.Kebabian, JW, Calne, DB.Multiple receptors for dopamine. Nature 1979; 277: 93–93.CrossRefGoogle ScholarPubMed
10.Seeman, P, Grigoriadis, D, George, SR, et al. Functional states of dopamine receptors. In: Woodruff, GN, Creese, I, Cessa, GL, et al eds. Dopaminergic Systems and Their Regulation. London: Mac-Millan Press. 1984.Google Scholar
11.Seeman, P.Brain dopamine receptors. Pharmacol Review. 1980; 32: 229–313.Google ScholarPubMed
12.Kornhuber, J, Komhuber, ME.Presynaptic dopaminergic modulation of cortical input to the striatum. Life Sci 1986; 39: 669–674.CrossRefGoogle ScholarPubMed
13.Trugman, JM, IIGeary, WA, Wooten, GF. Localization of D-2 dopamine receptors to intrinsic striatal neurons by quantitative autoradiography. Nature 1986; 323: 267–269.CrossRefGoogle ScholarPubMed
14.Uhl, GR, Hackney, GO, Torchia, M, et al. Parkinson’s disease: nigral receptor changes support peptidergic role in nigrostriatal modulation. Ann Neurol 1986; 20: 194–203.CrossRefGoogle ScholarPubMed
15.Staunton, DA, Magistetti, PJ, Koob, GF, et al. Dopaminergic super- sensitivity induced by denervation and chronic receptor blockade is additive. Nature 1982; 299: 72–74.CrossRefGoogle Scholar
16.Lee, T, Seeman, P, Rajput, A, et al. Receptor basis for dopaminergic supersensitivity in Parkinson’s disease. Nature 1978; 273: 59–61.CrossRefGoogle ScholarPubMed
17.Guttman, M, Seeman, P.L-dopa reverses the elevated density of D2 dopamine receptors in Parkinson’s diseased striatum. J Neural Trans 1985;64:93–103.CrossRefGoogle ScholarPubMed
18.Rinne, UK.Brain neurotransmitter receptors in Parkinson’s disease. In: Marsden, CD, Fahn, S, eds. Movement Disorders. London: 1982, 59–74.Google Scholar
19.Guttman, M, Seeman, P, Reynolds, , et al. Dopamine D2 receptor density remains constant in treated Parkinson’s disease. Ann Neurol 1986; 19: 487–492.CrossRefGoogle ScholarPubMed
20.Bokobza, B, Ruberg, M, Scatton, B, et al. [3H] spiperone binding, dopamine and HVA concentrations in Parkinson’s disease and Supranuclear Palsy. Eur J Pharmacol 1984; 99: 167–175.CrossRefGoogle ScholarPubMed
21.Baron, JC, Maziere, B, Loc’h, C, et al. Loss of striatal [76Br] bromospiperone binding sites demonstrated by positron tomography in progressive Supranuclear Palsy. J Cereb Blood Flow Metab 1986; 6: 131–136.CrossRefGoogle ScholarPubMed
22.Quik, M, Spokes, E, Mackay, A, et al. Alterations in 3H-spiperone binding in human caudate nucleus, substantia nigra and frontal cortex in the Shy-Drager Syndrome and Parkinson’s disease. J Neurol Sci 1979; 43: 429–437.CrossRefGoogle Scholar
23.Cross, A, Rossor, M.Dopamine D-1 and D-2 receptors in Huntington’s disease. Eur J Pharmacol 1983; 88: 223–229.CrossRefGoogle ScholarPubMed
24.Seeman, P, Ulpian, C, Bergeron, C, et al. Bimodal distribution of dopamine receptor densities in brains of schizophrenics. Science 1984: 728–731.CrossRefGoogle ScholarPubMed
25.Porceddu, ML, Giorg, O, Orgini, E, et al. 3H-SCH 23390 binding sites in the rat substantia nigra: evidence for a presynaptic localization and inervation by dopamine. Life Sci 1986; 39: 321–329.CrossRefGoogle Scholar
26.Raisman, R, Cash, R, Ruberg, M, et al. Binding of [3H]-SCH 23390 to D-l receptors in the putamen of control and parkinsonian subjects. Eur J Pharm 1985; 113: 467–468.CrossRefGoogle Scholar
27.Penney, JB, Pan, HS, Young, AB, et al. Quantitative autoradiography of [3H] muscimol binding in rat brain. Science 1981; 214: 1036–1038.CrossRefGoogle ScholarPubMed
28.Lloyd, KG, Shemen, L, Hornykiewicz, O.Distribution of high affinity sodium-independent [3H]-gamma-aminobutyric acid ([3H]-GABA) binding in the human brain: alterations in Parkinson’s disease. Brain Res 1977; 127: 269–278.CrossRefGoogle Scholar
29.Walker, FO, Young, AB, Penney, JB, et al. Benzodiazepine and GABA receptors in early Huntington’s disease. Neurology 1984; 34: 1237–1240.CrossRefGoogle ScholarPubMed
30.Van Ness, BC, Walkers, AE, Bergman, MO, et al. Gamma-amino-butyric acid receptors in normal brain and Huntington’s disease. Neurology 1982; 32: 63–68.CrossRefGoogle Scholar
31.Whitehouse, PJ, Trifiletti, RR, Jones, BE, et al. Neurotransmitter receptor alterations in Huntington’s disease: autoradiographic and homogenate studies with special reference to benzodiazepine receptor complexes. Ann Neurol 1985; 18: 202–210.CrossRefGoogle ScholarPubMed
32.Rinne, UK, Koskinen, V, Laaksonen, , et al. GABA receptor binding in the Parkinsonian brain. Life Sci 1978; 22: 2225–2228.CrossRefGoogle ScholarPubMed
33.Lo, MMS, Niehoff, DL, Kuhar, MJ, et al. Differential localization of type 1 and type II benzodiazepine binding sites in substantia nigra. Nature 1983; 306: 57–60.CrossRefGoogle Scholar
34.Samson, Y, Hantraye, P, Baron, JC, et al. Kinetics and displacement of [11C] R015-1788, a benzodiazepine antagonist, studied in human brain invivo by positron tomography. Eur J Pharmacol 1985; 110: 247–251.CrossRefGoogle Scholar
35.Corda, MG, Concas, A, Porceddu, ML, et al. Striato-nigral denervation increases type II benzodiazepine receptors in the substantia nigra of the rat. Neuropharm 1986; 25: 59–62.CrossRefGoogle ScholarPubMed
36.Starr, MS.Multiple opiate receptors may be involved in suppressing gama aminobutyrate release in substantia nigra. Life Sci 1985; 37: 2249–2255.CrossRefGoogle Scholar
37.Abou-Khalil, B, Young, AB, Penney, B.Evidence for the presynaptic localization of opiate binding sites on striatal efferent fibres. Brain Res 1984; 323: 21–29.CrossRefGoogle Scholar
38.Moskowitz, AS, Goodman, RR.Light microscopic autoradiographic localization of mu and lambda opioid binding sites in the mouse central nervous system. J Neurosci 1984; 4: 1331–1342.CrossRefGoogle Scholar
39.Garnder, EL, Zukin, RS, Makman, MH.Modulation of opiate receptor binding in striatum and amygdala by selective mesencephalic lesions. Brain Res 1980; 194: 232–239.Google Scholar
40.Reisine, TD, Rossor, M, Spokes, E, et al. Alterations in brain opiate receptors in Parkinson’s disease. Brain Res 1979; 173: 378–382.CrossRefGoogle ScholarPubMed
41.Birdsall, NJM, Hulme, EC.Muscarinic receptor subclasses. TIPS 1983: 459–463.Google ScholarPubMed